Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
291.77
-2.83 (-0.96%)
At close: Aug 17, 2026, 4:00 PM EDT
290.31
-1.46 (-0.50%)
Pre-market: Aug 18, 2026, 7:39 AM EDT
Ligand Pharmaceuticals Revenue
Ligand Pharmaceuticals had revenue of $63.69M in the quarter ending June 30, 2026, with 33.73% growth. This brings the company's revenue in the last twelve months to $290.54M, up 54.89% year-over-year. In the year 2025, Ligand Pharmaceuticals had annual revenue of $268.09M with 60.40% growth.
Revenue (ttm)
$290.54M
Revenue Growth
+54.89%
P/S Ratio
20.02
Revenue / Employee
$6,181,745
Employees
47
Market Cap
5.82B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 268.09M | 100.95M | 60.40% |
| Dec 31, 2024 | 167.13M | 35.82M | 27.28% |
| Dec 31, 2023 | 131.31M | -64.93M | -33.09% |
| Dec 31, 2022 | 196.25M | -45.30M | -18.75% |
| Dec 31, 2021 | 241.54M | 77.98M | 47.68% |
| Dec 31, 2020 | 163.56M | 43.28M | 35.98% |
| Dec 31, 2019 | 120.28M | -131.17M | -52.17% |
| Dec 31, 2018 | 251.45M | 110.35M | 78.21% |
| Dec 31, 2017 | 141.10M | 32.13M | 29.48% |
| Dec 31, 2016 | 108.97M | 37.06M | 51.53% |
| Dec 31, 2015 | 71.91M | 7.38M | 11.43% |
| Dec 31, 2014 | 64.54M | 15.57M | 31.78% |
| Dec 31, 2013 | 48.97M | 17.59M | 56.02% |
| Dec 31, 2012 | 31.39M | 1.35M | 4.50% |
| Dec 31, 2011 | 30.04M | 6.50M | 27.61% |
| Dec 31, 2010 | 23.54M | -15.40M | -39.55% |
| Dec 31, 2009 | 38.94M | 11.63M | 42.56% |
| Dec 31, 2008 | 27.32M | 14.42M | 111.84% |
| Dec 31, 2007 | 12.89M | 8.92M | 224.21% |
| Dec 31, 2006 | 3.98M | -6.24M | -61.07% |
| Dec 31, 2005 | 10.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.01B |
| Caris Life Sciences | 989.61M |
| Mirum Pharmaceuticals | 618.07M |
| Travere Therapeutics | 591.33M |
| CRISPR Therapeutics AG | 13.39M |
| Xenon Pharmaceuticals | 7.50M |
| Dianthus Therapeutics | 1.90M |
LGND News
- 1 day ago - Ligand price target raised to $390 from $387 at Citi - TheFly
- 1 day ago - Ligand initiated with an Outperform at Leerink - TheFly
- 11 days ago - Ligand price target raised to $345 from $340 at RBC Capital - TheFly
- 11 days ago - Ligand price target raised to $358 from $289 at H.C. Wainwright - TheFly
- 12 days ago - Ligand Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 12 days ago - Ligand Pharmaceuticals Earnings release: Q2 2026 - Filings
- 12 days ago - Ligand Pharmaceuticals Slides: Q2 2026 - Filings
- 12 days ago - Ligand Pharmaceuticals Quarterly report: Q2 2026 - Filings